Brokerages Anticipate Repligen Co. (NASDAQ:RGEN) Will Post Quarterly Sales of $189.41 Million

Wall Street brokerages expect that Repligen Co. (NASDAQ:RGENGet Rating) will report sales of $189.41 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Repligen’s earnings. The highest sales estimate is $192.40 million and the lowest is $183.00 million. Repligen reported sales of $162.96 million during the same quarter last year, which indicates a positive year-over-year growth rate of 16.2%. The firm is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Repligen will report full-year sales of $786.72 million for the current year, with estimates ranging from $773.40 million to $792.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $890.58 million, with estimates ranging from $849.00 million to $948.60 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Repligen.

Repligen (NASDAQ:RGENGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.20. Repligen had a net margin of 19.86% and a return on equity of 11.13%. The company had revenue of $206.40 million during the quarter, compared to analysts’ expectations of $185.48 million. During the same quarter in the prior year, the company posted $0.68 EPS. The business’s revenue was up 44.5% on a year-over-year basis.

A number of equities analysts have recently issued reports on RGEN shares. Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 price objective for the company. in a research note on Monday, February 21st. StockNews.com started coverage on shares of Repligen in a research report on Thursday, March 31st. They set a “hold” rating for the company. SVB Leerink dropped their target price on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday, February 18th. Finally, Craig Hallum dropped their target price on shares of Repligen from $286.00 to $274.00 in a research report on Thursday, April 28th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $285.57.

Shares of RGEN stock opened at $150.40 on Monday. Repligen has a 52-week low of $137.21 and a 52-week high of $327.32. The stock has a market cap of $8.19 billion, a price-to-earnings ratio of 59.45 and a beta of 0.98. The firm has a fifty day moving average of $166.73 and a 200-day moving average of $209.09.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total value of $396,060.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.10% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Greenleaf Trust boosted its stake in shares of Repligen by 4.2% in the 3rd quarter. Greenleaf Trust now owns 1,380 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 55 shares during the last quarter. Cetera Advisors LLC boosted its stake in shares of Repligen by 2.8% in the 3rd quarter. Cetera Advisors LLC now owns 2,121 shares of the biotechnology company’s stock valued at $613,000 after purchasing an additional 57 shares during the last quarter. Greenwood Capital Associates LLC boosted its stake in shares of Repligen by 1.7% in the 4th quarter. Greenwood Capital Associates LLC now owns 3,490 shares of the biotechnology company’s stock valued at $924,000 after purchasing an additional 60 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Repligen by 0.5% in the 3rd quarter. Arizona State Retirement System now owns 14,208 shares of the biotechnology company’s stock valued at $4,106,000 after purchasing an additional 64 shares during the last quarter. Finally, Intrust Bank NA boosted its stake in shares of Repligen by 3.6% in the 4th quarter. Intrust Bank NA now owns 1,908 shares of the biotechnology company’s stock valued at $505,000 after purchasing an additional 66 shares during the last quarter. Hedge funds and other institutional investors own 86.82% of the company’s stock.

Repligen Company Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.